Physician profile
Sheldon Brown
NPI 1972985273
$1,264.20
in general payments reported to CMS, 2019-2025
17 companies · $315 in 2025
The $315 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.73 · 2020: $225 · 2021: $30.38 · 2023: $348 · 2024: $249 · 2025: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $911.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $911.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $228.17 | 2019-2025 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $194.40 | 2019-2025 | Ingrezza |
| Abbvie INC. | $185.25 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $111.56 | 2023-2024 | Caplyta |
| Ironshore Pharmaceuticals INC. | $77.65 | 2019-2020 | |
| Allergan, INC. | $77.55 | 2019-2020 | |
| Lundbeck LLC | $62.59 | 2023-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Supernus Pharmaceuticals, INC. | $57.48 | 2024-2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $56.46 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $45.85 | 2025 | Cobenfy |
| Alkermes, INC. | $37.39 | 2024 | Aristada, Lybalvi |
| Noven Therapeutics, LLC | $35.96 | 2023-2025 | Xelstrym |
| Harmony Biosciences LLC | $32.69 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $25.94 | 2020-2024 | Austedo Xr |
| Idorsia Pharmaceuticals US INC | $13.64 | 2024 | Quviviq |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $12.28 | 2020 | |
| Corium, LLC | $9.34 | 2024 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheldon Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.